Your browser is no longer supported. Please, upgrade your browser.
Settings
MNKD MannKind Corporation daily Stock Chart
MNKD [NASD]
MannKind Corporation
Index- P/E- EPS (ttm)-0.36 Insider Own0.40% Shs Outstand180.92M Perf Week3.54%
Market Cap211.68M Forward P/E- EPS next Y-0.24 Insider Trans3.75% Shs Float178.95M Perf Month9.35%
Income-61.20M PEG- EPS next Q-0.07 Inst Own27.20% Short Float23.10% Perf Quarter-7.87%
Sales53.00M P/S3.99 EPS this Y46.40% Inst Trans1.10% Short Ratio19.49 Perf Half Y-21.48%
Book/sh-1.04 P/B- EPS next Y28.10% ROA-72.90% Target Price3.00 Perf Year3.54%
Cash/sh0.18 P/C6.43 EPS next 5Y26.80% ROE32.00% 52W Range0.94 - 3.04 Perf YTD10.38%
Dividend- P/FCF- EPS past 5Y28.40% ROI106.90% 52W High-62.17% Beta2.33
Dividend %- Quick Ratio0.60 Sales past 5Y- Gross Margin55.80% 52W Low22.34% ATR0.07
Employees225 Current Ratio0.60 Sales Q/Q102.70% Oper. Margin- RSI (14)54.37 Volatility6.24% 6.83%
OptionableYes Debt/Eq- EPS Q/Q81.90% Profit Margin- Rel Volume0.66 Prev Close1.17
ShortableYes LT Debt/Eq- EarningsAug 07 AMC Payout- Avg Volume2.12M Price1.15
Recom1.30 SMA204.07% SMA502.45% SMA200-20.77% Volume1,367,858 Change-1.71%
May-14-19Initiated BTIG Research Buy $3
Mar-04-19Initiated SVB Leerink Outperform $3
Feb-22-19Initiated SVB Leerink Outperform $3
Feb-28-18Downgrade Maxim Group Hold → Sell $1
Nov-01-17Downgrade Maxim Group Buy → Hold
Oct-10-17Initiated H.C. Wainwright Buy $7
Oct-06-17Reiterated Maxim Group Buy $4 → $7
Aug-11-17Initiated Maxim Group Buy $4
May-10-16Reiterated RBC Capital Mkts Underperform $0.15 → $0.20
May-10-16Reiterated Piper Jaffray Underweight $0.05 → $0.10
Jan-06-16Reiterated RBC Capital Mkts Underperform $1 → $0.15
Jan-06-16Reiterated Piper Jaffray Underweight $1.50 → $0.05
Nov-04-15Downgrade RBC Capital Mkts Outperform → Underperform $9 → $1
Sep-09-15Downgrade Piper Jaffray Neutral → Underweight
Aug-03-15Reiterated RBC Capital Mkts Outperform $10 → $9
May-11-15Reiterated MLV & Co Hold $7 → $4
May-11-15Downgrade JP Morgan Neutral → Underweight
Apr-16-15Reiterated RBC Capital Mkts Outperform $13 → $10
Aug-12-14Reiterated RBC Capital Mkts Outperform $16 → $13
Jul-01-14Downgrade MLV & Co Buy → Hold $11
Aug-16-19 08:35AM  Edited Transcript of MNKD earnings conference call or presentation 7-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
Aug-08-19 11:23AM  MannKind Corporation (MNKD) Q2 2019 Earnings Call Transcript Motley Fool
Aug-07-19 04:01PM  MannKind Corporation Reports 2019 Second Quarter Financial Results and Recent Business Highlights GlobeNewswire
Aug-05-19 09:00AM  MannKind and One Drop Sign Collaboration Agreement to Integrate Bluetooth-Connected Inhaler with Dose Detection into the One Drop Platform GlobeNewswire -5.08%
Aug-01-19 05:02PM  MannKind Corporation to Hold 2019 Second Quarter Financial Results Conference Call on August 7, 2019 GlobeNewswire
Jul-31-19 09:00AM  Afrezza® Safety and Pharmacokinetics Study in Pediatric Patients Opens Enrollment for Cohort 3 GlobeNewswire
Jul-18-19 08:52AM  MannKind Repays Maturing Debt Obligation; Buys Back Certain Warrants GlobeNewswire
Jul-15-19 09:00AM  MannKind Partners with GoodRx to Help Raise Awareness on Reducing Out of Pocket Insulin Cost for Patients GlobeNewswire
Jul-11-19 04:14PM  MannKind Expands Commercial Scale Manufacturing Capabilities for High-Potency Molecules GlobeNewswire -5.26%
Jul-09-19 12:09PM  What Kind Of Shareholders Own MannKind Corporation (NASDAQ:MNKD)? Simply Wall St.
Jun-14-19 10:00AM  MNKD: ADA Presentations: Positive Pediatric Data Lends Support for Anticipated Pivotal Study. Adult Data Highlights Benefits, Safety of Higher Doses Zacks Small Cap Research
Jun-12-19 09:00AM  MannKind to Present at the JMP Securities Life Sciences Conference GlobeNewswire
Jun-09-19 02:00PM  MannKind Presents Positive Afrezza® Clinical Data from Three Studies at ADA 79th Scientific Sessions GlobeNewswire
Jun-03-19 08:00AM  Afrezza® (insulin human) Inhalation Powder Approved in Brazil GlobeNewswire +6.03%
May-18-19 08:03AM  2 Healthcare Stocks That Could Double Your Money Motley Fool
May-17-19 08:03AM  The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering Benzinga
May-16-19 04:01PM  MannKind Announces Afrezza® Distribution Agreement in Australia GlobeNewswire
May-14-19 03:47PM  Why MannKind Is Up Big Today Motley Fool +7.32%
10:00AM  MNKD: Product Sales Up 49% on 71% Growth in Demand. Product Margin Continues to Expand Zacks Small Cap Research
May-08-19 09:24AM  MannKind Corporation (MNKD) Q1 2019 Earnings Call Transcript Motley Fool -6.21%
May-07-19 05:53PM  Edited Transcript of MNKD earnings conference call or presentation 7-May-19 1:00pm GMT Thomson Reuters StreetEvents -6.45%
08:19AM  MannKind: 1Q Earnings Snapshot Associated Press
08:00AM  MannKind Corporation Reports 2019 First Quarter Financial Results GlobeNewswire
May-02-19 09:26AM  United Therapeutics (UTHR) Down Despite Q1 Earnings Beat Zacks
Apr-30-19 09:00AM  MannKind Corporation to Hold 2019 First Quarter Financial Results Conference Call on May 7, 2019 GlobeNewswire
Apr-25-19 09:45AM  MannKind Presents Scientific Data at 28th Annual Scientific and Clinical Congress of the American Association of Clinical Endocrinologists (AACE 2019) GlobeNewswire
Apr-02-19 06:00AM  MannKind to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire
Apr-01-19 06:00AM  MannKind Receives $12.5 Million Milestone Payment from United Therapeutics GlobeNewswire -8.63%
Mar-14-19 09:00AM  MannKind to Sponsor Andretti Autosport Type 1 Diabetes Driver, Conor Daly GlobeNewswire +6.16%
Mar-13-19 03:00PM  These Four Healthcare Stocks Are Making Moves on Wednesday ACCESSWIRE
Mar-06-19 01:09PM  Edited Transcript of MNKD earnings conference call or presentation 26-Feb-19 2:00pm GMT Thomson Reuters StreetEvents
Mar-05-19 10:55AM  MNKD: A Head Start to 2019; Q4 and Annual 2018 Earnings Results Zacks Small Cap Research +5.23%
Feb-26-19 05:55PM  MannKind Corp (MNKD) Q4 2018 Earnings Conference Call Transcript Motley Fool +16.56%
04:43PM  Here's Why MannKind Rocketed Higher Today Motley Fool
08:00AM  MannKind Corporation Fourth Quarter and Year-End 2018 Earnings Call GlobeNewswire
07:00AM  MannKind Corporation to Host Earnings Call ACCESSWIRE
Feb-25-19 01:28PM  Q4 Earnings Outlook For MannKind Benzinga
Feb-21-19 07:32AM  The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan Benzinga
Feb-20-19 05:00PM  MannKind Presents New Scientific Data at 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019) GlobeNewswire
09:00AM  MannKind Corporation Participating at Upcoming Conferences GlobeNewswire
Feb-19-19 04:31PM  MannKind Corporation to Hold 2018 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2019 GlobeNewswire
Feb-05-19 10:24AM  Weekly CFO Buys Highlight GuruFocus.com
08:00AM  Market Trends Toward New Normal in MannKind, IDEX, Belden, Bright Horizons Family Solutions, Masonite International, and Veritiv Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Jan-21-19 10:45AM  MNKD: Update From Our Meeting With MNKD at JPM Zacks Small Cap Research
09:00AM  Biotech Stocks on the Move ACCESSWIRE
Jan-17-19 05:14AM  How to spot risky biotech companies and six to avoid now MarketWatch
Jan-16-19 04:30PM  MannKind Announces Direct Purchase Insulin Program Providing Afrezza® for as low as $4 a Day GlobeNewswire
Dec-27-18 08:00AM  MannKind Corporation to Hold Investor Conference Call GlobeNewswire
Dec-20-18 12:11PM  How Many MannKind Corporation (NASDAQ:MNKD) Shares Do Institutions Own? Simply Wall St. -32.54%
10:20AM  Why MannKind Stock Is Plunging Today Motley Fool
07:00AM  Today's Research Reports on Trending Tickers: Spectrum Pharmaceuticals and MannKind ACCESSWIRE
Dec-19-18 11:57PM  MannKind Announces Pricing of $40 Million Public Offering GlobeNewswire
04:01PM  MannKind Announces Commencement of Public Offering GlobeNewswire
Dec-11-18 10:00AM  MNKD: Zacks SCR Initiates Coverage of MannKind With $4.25/share Price Target Zacks Small Cap Research
Dec-10-18 11:00AM  Biotech Stocks Beating the Market ACCESSWIRE
Nov-27-18 09:00AM  MannKind Appoints Christine Mundkur to its Board of Directors GlobeNewswire
05:00AM  Analysts: Why United Therapeutics has had a streak of licensing deals American City Business Journals
Nov-16-18 05:48PM  Edited Transcript of MNKD earnings conference call or presentation 1-Nov-18 1:00pm GMT Thomson Reuters StreetEvents
Nov-01-18 09:33AM  MannKind: 3Q Earnings Snapshot Associated Press
08:00AM  MannKind Corporation Reports 2018 Third Quarter Financial Results GlobeNewswire
Oct-31-18 02:46PM  United Therapeutics Corp (UTHR) Q3 2018 Earnings Conference Call Transcript Motley Fool
Oct-25-18 05:00PM  MannKind Corporation to Hold 2018 Third Quarter Financial Results Conference Call on November 1, 2018 GlobeNewswire
Oct-24-18 07:20AM  Research Report Identifies Cato, Roadrunner Transportation, Talend S.A, Vi, MannKind, and Acceleron Pharma with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Oct-17-18 08:00AM  Todays Research Reports on Stocks to Watch: Altimmune and MannKind ACCESSWIRE
Oct-16-18 05:22PM  Why MannKind Corp. Soared 16.4% Tuesday Motley Fool +16.36%
06:00AM  United Therapeutics And MannKind Announce Closing Of License And Collaboration Agreement PR Newswire
06:00AM  United Therapeutics and MannKind Announce Closing of License and Collaboration Agreement GlobeNewswire
Oct-15-18 09:00AM  Afrezza® Inhaled Insulin Television Advertising Campaign Wins Gold Award for Creativity GlobeNewswire
Oct-11-18 09:51AM  Here's What Sent MannKind Corporation Soaring 66.4% in September Motley Fool -8.98%
Oct-04-18 09:00AM  MannKind Presents Positive Afrezza® STAT Study Clinical Data at 54th Annual Meeting of the European Association for the Study of Diabetes GlobeNewswire
Oct-03-18 09:00AM  MannKind Presents New Scientific Data at 54th Annual Meeting of the European Association for the Study of Diabetes GlobeNewswire +7.14%
Sep-27-18 02:25PM  MannKind Stock History Motley Fool
Sep-24-18 09:00AM  MannKind Announces Completion of Cohort 1 and Opens Enrollment for Cohort 2 of Afrezza® Safety and Pharmacokinetics Study in Pediatric Patients GlobeNewswire +10.34%
Sep-19-18 04:42AM  Edited Transcript of MNKD earnings conference call or presentation 2-Aug-18 9:00pm GMT Thomson Reuters StreetEvents
Sep-13-18 09:00AM  Positive Afrezza® Clinical Data from STAT Study Published in Diabetes Technology & Therapeutics GlobeNewswire
Sep-10-18 08:54AM  Implied Volatility Surging for MannKind (MNKD) Stock Options Zacks +10.67%
08:05AM  Mannkind Afrezza Sales Have Doubled and Treprostinil is Getting Some Traction ACCESSWIRE
Sep-08-18 07:50PM  Is MannKind Corporation Stock a Buy? Motley Fool
07:16AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Sep-06-18 03:02PM  A New Deal Moves MannKind Back From the Brink Motley Fool -6.85%
08:52AM  The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals Zacks
Sep-05-18 04:56PM  New Development Partnership Could Pay Off Big for MannKind Stock InvestorPlace +5.29%
04:30PM  Why Cronos Group, MannKind, and Vera Bradley Jumped Today Motley Fool
11:12AM  MannKind Stock Up on Licensing Deal With United Therapeutics Zacks
10:30AM  The Probable Reason Why MannKind Corporation Is Rallying Again Motley Fool
09:39AM  Biotech Stock Roundup: AMGN, PBYI Get EC Nod for Their Drugs, MNKD Soars Zacks
Sep-04-18 11:27AM  Why MannKind Stock Is Skyrocketing Today InvestorPlace +89.09%
10:06AM  Why MannKind Corporation Stock Is Skyrocketing Today Motley Fool
09:30AM  3 Stocks to Watch As The Healthcare Sector Heats Up ACCESSWIRE
09:19AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:54AM  United Therapeutics strikes nine-figure deal to commercialize new form of drug delivery American City Business Journals
Aug-29-18 09:00AM  MannKind Corporation to Present at Upcoming Conferences GlobeNewswire
Aug-28-18 07:30AM  Analysis: Positioning to Benefit within MannKind, Chimerix, Superior Energy Services, Marinus Pharmaceuticals, Airgain, and Eagle Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Aug-23-18 02:31PM  Los Angeles stocks that are driving Wall Street's latest bull run American City Business Journals
Aug-09-18 08:35AM  Are Options Traders Betting on a Big Move in MannKind (MNKD) Stock? Zacks
Aug-06-18 04:30PM  Why MannKind Corporation Stock Is Tanking Again Today Motley Fool -12.17%
10:24AM  MannKind Stock Is One Step Away From Obliteration InvestorPlace
Aug-03-18 01:34PM  Can MannKind Corporation Avert Bankruptcy? Motley Fool -23.33%
08:00AM  Today's Research Reports on Trending Tickers: Tesaro and MannKind ACCESSWIRE
Aug-02-18 06:25PM  MannKind (MNKD) Reports Q2 Loss, Misses Revenue Estimates Zacks
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States. The company has a licensing and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. MannKind Corporation was founded in 1991 and is headquartered in Westlake Village, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tross Stuart AChief People & Workpl OfficerJul 31Buy0.955,0004,750121,785Jul 31 08:47 PM
Kendall David MChief Medical OfficerJul 31Buy0.955,0004,75049,850Jul 31 08:44 PM
McCauley PatrickChief Commercial OfficerJul 31Buy0.955,0004,75095,433Jul 31 08:44 PM
Barton CourtneyChief Compl & Privacy OfficerJul 31Buy0.954,0113,81029,584Jul 31 08:43 PM
Binder Steven B.Chief Financial OfficerJul 31Buy0.952,1392,03246,036Jul 31 08:40 PM
Castagna MichaelChief Executive OfficerJul 31Buy0.955,0004,750163,560Jul 31 08:41 PM
Binder Steven B.Chief Financial OfficerJan 31Buy1.071,8601,9903,620Jan 31 06:19 PM
Tross Stuart ACorp VP, Chief People OfficerJan 31Buy1.075,0005,35080,040Jan 31 06:15 PM
McCauley PatrickChief Commercial OfficerJan 31Buy1.075,0005,35050,165Jan 31 06:14 PM
Kendall David MChief Medical OfficerJan 31Buy1.075,0005,3507,824Jan 31 06:12 PM
Ingram Elizabeth GarrettChief Marketing OfficerJan 31Buy1.075,0005,35031,141Jan 31 06:11 PM
Barton CourtneyChief Compliance OfficerJan 31Buy1.075,0005,35012,000Jan 31 06:05 PM
Castagna MichaelChief Executive OfficerJan 31Buy1.075,0005,35098,157Jan 31 06:03 PM